These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2183724)

  • 61. The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization.
    Nissenson AR; Mayne TJ; Krishnan M
    Am J Kidney Dis; 2011 Apr; 57(4):550-2. PubMed ID: 21333425
    [No Abstract]   [Full Text] [Related]  

  • 62. The 2011 ESRD prospective payment system: perspectives of a home dialysis patient advocate.
    Peckham B
    Am J Kidney Dis; 2011 Apr; 57(4):559-61. PubMed ID: 21333429
    [No Abstract]   [Full Text] [Related]  

  • 63. Prescription drugs in Medicare and the ESRD program.
    Powe NR
    Semin Nephrol; 2000 Nov; 20(6):535-42. PubMed ID: 11111855
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are cost pressures influencing the way nephrologists provide care?
    Dubman R
    Nephrol News Issues; 2014 Mar; 28(3):22, 24, 33. PubMed ID: 24720012
    [No Abstract]   [Full Text] [Related]  

  • 65. ESRD in the geriatric population: the crisis of managed care and the opportunity of disease management.
    Steinman TI
    Semin Dial; 2002; 15(2):84-7. PubMed ID: 11952931
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regional Variations in the Interpretation of the End-Stage Renal Disease Thirty-Month Coordination Period: Potential Implications for Patient Care.
    Harford R; Clark MJ; Yan G; Flaque J; Colon J; Torre F; Rodriguez Y; Norris KC
    J Health Care Poor Underserved; 2017; 28(4):1245-1253. PubMed ID: 29176092
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Kidneys, ethics, and politics: policy lessons of the ESRD experience.
    Caplan AL
    J Health Polit Policy Law; 1981; 6(3):488-503. PubMed ID: 7033349
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The 2011 ESRD prospective payment system and the survival of an endangered species: the perspective of a not-for-profit medium-sized dialysis organization.
    Johnson DS; Meyer KB; Johnson HK
    Am J Kidney Dis; 2011 Apr; 57(4):553-5. PubMed ID: 21333427
    [No Abstract]   [Full Text] [Related]  

  • 69. Who should be paying for vitamin D analogues--Medicare or the patients?
    Hall G
    Nephrol Nurs J; 2006; 33(3):345-6, 351. PubMed ID: 16859205
    [No Abstract]   [Full Text] [Related]  

  • 70. Hospice and ESRD: knowledge deficits and underutilization of program benefits.
    Thompson KF; Bhargava J; Bachelder R; Bova-Collis R; Moss AH
    Nephrol Nurs J; 2008; 35(5):461-6, 502; quiz 467-8. PubMed ID: 18856076
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Medicare program; end-stage renal disease (ESRD) payment exception requests and organ procurement costs--HCFA. Final rule.
    Fed Regist; 1997 Aug; 62(158):43657-74. PubMed ID: 10169837
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The IOM report: an A+ for effort, but will it survive Washington's budget-cutting mood?
    Hull AR
    Nephrol News Issues; 1991 May; 5(5):28-9. PubMed ID: 1961288
    [No Abstract]   [Full Text] [Related]  

  • 73. Palliative dialysis in end-stage renal disease.
    Trivedi DD
    Am J Hosp Palliat Care; 2011 Dec; 28(8):539-42. PubMed ID: 21398269
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Changes to the end-stage renal disease quality incentive program.
    Fishbane S; Miller I; Wagner JD; Masani NN
    Kidney Int; 2012 Jun; 81(12):1167-71. PubMed ID: 22534963
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ESRD program projections and experience.
    Klar RM
    JAMA; 1979 Jan; 241(3):239-40. PubMed ID: 364079
    [No Abstract]   [Full Text] [Related]  

  • 76. ESRD centers deserve a level playing field..
    Nidetz M
    Nephrol News Issues; 1989 Nov; 3(11):22-4. PubMed ID: 2594107
    [No Abstract]   [Full Text] [Related]  

  • 77. A review of the end stage renal disease program.
    Bauers CM
    Nephrol Nurse; 1983; 5(4):17-22. PubMed ID: 6353257
    [No Abstract]   [Full Text] [Related]  

  • 78. Toward population management in an integrated care model.
    Maddux FW; McMurray S; Nissenson AR
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):694-700. PubMed ID: 23539229
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Medicare secondary payer program: Part I.
    Breskin W
    Med Interface; 1994 Jun; 7(6):137-8, 140. PubMed ID: 10171896
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is HCFA's reimbursement policy controlling quality of care for end-stage renal disease patients?
    Lockridge RS; McKinney JK
    ASAIO J; 2001; 47(5):466-8. PubMed ID: 11575817
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.